Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
Technology appraisal guidance
Reference number: TA1113
Published:
Please note that following on from information received from the company, the timelines for this appraisal have now been revised and the appraisal is now anticipated to begin in late July 2024.